Trastuzumab Rezetecan Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC
Clinical trial NCT07047755 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07047755
- Sponsor
- Henan Cancer Hospital
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-07-01
- Primary completion
- 2026-07-01
- Enrollment
- 48
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.